Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma

* Investment will accelerate the overall Sarclisa® development program
* Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa®
PARIS -... | March 15, 2022

Related Keywords

United States ,Paris ,France General ,France ,Eva Schaefer Jansen ,Nicholas Galakatos ,Corentine Driancourt ,Felix Lauscher ,John Reed ,Kate Conway ,Paula Chirhart ,Nathalie Pham ,Sandrine Guendoul ,Sally Bain ,Priya Nanduri ,Drug Administration ,Injections Inc ,Nasdaq ,Global Head Of Research ,Global Head Of Blackstone Life Sciences ,European Union ,International Myeloma Foundation ,Euronext ,Blackstone Life Sciences ,Blackstone Life ,Nonproprietary Naming ,Biological Products Guidance ,Life Sciences ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Blackstone Inc Stock Exchange ,News ,Information ,Press Release ,Investment ,Hill ,Ccelerate ,The ,Verall ,Development ,Sanofi ,Ontinue ,O ,Bully ,Manage ,Linical ,Program ,End ,Etain ,Bull ,Tights ,Control ,F Bx Us09260d1072 ,